#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Cannabis hyperemesis syndrome represents an increasingly common diagnosis that clinicians must recognize and differentiate from other causes of severe nausea and vomiting, particularly given the rising prevalence of high-potency cannabis products in circulation. The dramatic increase in CHS-related emergency department visits documented over the past decade suggests this condition warrants integration into standard differential diagnostic algorithms for hyperemesis presentations. Early identification and counseling regarding cannabis cessation remains the only evidence-based intervention, making provider awareness critical to reducing unnecessary diagnostic testing and hospitalizations.
Cannabis hyperemesis syndrome (CHS) diagnoses have increased dramatically over the past decade, with a 2025 study documenting 4.4 emergency department visits per 100,000 population attributable to CHS, reflecting a significant public health trend. The syndrome presents with cyclic nausea, vomiting, and abdominal pain in chronic cannabis users and is thought to result from cannabinoid receptor overstimulation in the gastrointestinal tract, though the precise mechanism remains incompletely understood. Rising CHS prevalence correlates with increased cannabis potency and frequency of use, particularly among daily users consuming high-THC products. Clinicians should maintain a high index of suspicion for CHS in patients with refractory nausea and vomiting who report regular cannabis use, as the condition is often initially misdiagnosed and subjected to unnecessary diagnostic workup. The definitive treatment remains cannabis cessation, though symptom management during acute episodes may include antiemetics and supportive care. Patients and providers should recognize that CHS represents a genuine clinical entity associated with modern cannabis use patterns and that cessation remains the only evidence-based cure.
“Cannabinoid Hyperemesis Syndrome represents a real and increasingly common presentation in my practice, particularly among patients using high-potency products daily, and I’ve found that early recognition and complete cessation of cannabis use remains the only reliably effective treatment, though many patients struggle with this intervention once dependence has developed.”
💊 Cannabis hyperemesis syndrome represents an increasingly recognized clinical entity that warrants heightened awareness as cannabis use and potency have expanded substantially in recent years. While the reported rise in CHS diagnoses is striking, clinicians should consider that increased recognition, improved diagnostic criteria, and expanded cannabis access likely contribute to higher case counts alongside any true increase in incidence. The syndrome’s presentation can mimic other causes of intractable nausea and vomiting, including cyclic vomiting disorder and gastroparesis, so a careful history specifically targeting cannabis use patterns and symptom relief with cessation remains essential for accurate diagnosis. Given the potential for diagnostic delay and unnecessary investigations in patients with unrecognized CHS, incorporating direct questioning about cannabis consumption frequency and potency into the evaluation of unexplained hyperemesis may help providers identify this condition earlier and counsel patients on the risk of continued use.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: